Systemic inflammatory cytokine profiles in patients with gout during flare, intercritical and treat-to-target phases: TNFSF14 as new biomarker
Authors' conclusion
Gout flare involves multiple inflammatory mediators that may be used as potential therapeutic targets.
Study context
- Population
- Prospective gout population (GOUTROS); validation in an independent cohort (OLT1177–05)
- Comparison
- Plasma inflammatory proteins at gout flare (T1) vs intercritical phase (T2) vs serum urate target under ULT (T3)
- Outcome
- Levels of 92 inflammation-related plasma proteins across gout phases
Methodological detailsprospective cohort, targeted proteomics (Olink), independent validation cohort, ex vivo and in vitro experiments
- Prospective cohort
- Targeted proteomics (Olink)
- Independent validation cohort
- Ex vivo and in vitro experiments
Main finding
As reported in the abstract
Inflammatory new biomarkers differentially expressed during the three time-points
21
IL-6, colony-stimulating factor 1, vascular endothelial growth factor A and TNFSF14 increased during gout flare in an independent cohort
4
Original publication
Systemic inflammatory cytokine profiles in patients with gout during flare, intercritical and treat-to-target phases: TNFSF14 as new biomarker. Ann Rheum Dis. Published 12 June 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →